EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Constipation, IBs and the 5-HT 4 Receptor: What Role for Prucalopride?

Gareth J. Sanger, Eamonn M.M. Quigley

Clinical Medicine. Gastroenterology · 2010

DOI: 10.4137/cgast.s4136 ↗
AbstractBibliografische Angaben

Abstract

After the problems associated with the non-selective 5-HT 4 receptor agonists cisapride and tegaserod, the 5-HT 4 receptor is now beginning to come in from the cold. Thus, prucalopride is now the first of a new class of drug defined by selectivity and high intrinsic activity at the 5-HT 4 receptor. Prucalopride has been developed for treatment of chronic constipation rather than constipation-predominant irritable bowel syndrome (IBS). This follows the trend of first evaluating new gastrointestinal (GI) prokinetic drugs in disorders where disrupted GI motility is known to exist, rather than in a functional bowel disorder where changes in motility are uncertain. If prucalopride is not progressed towards the IBS indication, it has at least shown the way for other selective 5-HT 4 receptor agonists. Most notable among these is TD-5108 (velusetrag), also characterized by good selectivity at the 5-HT 4 receptor, high intrinsic activity and efficacy in patients with chronic constipation.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →